Inventiva is approaching one of the most important MASH readouts of the year with NATiV3, its pivotal Phase 3 trial of Lanifibranor in F2/F3 MASH.

In this episode, I break down:

• The different stages of MASH • The current market opportunity and competitors • Lanifibranor's Phase 2 data • Trial design for NATiV3 • Lanifibranor’s weight-gain and safety profile • Inventiva’s financing, dilution and unusual post-readout capital structure

NATiV3 could establish lanifibranor as another major MASH therapy — or expose the weaknesses hidden by a small Phase 2 study.

$IVA #biotech #MASH #NASH #lanifibranor #Inventiva

Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

This podcast is powered by Pinecast.

End of week wrap up stream.

Covered $CRBU, $LLY, $MRNA

This podcast is powered by Pinecast.

End of week biotech stream Oct 2, 2026.

Touched on $KOD, $BEAM, $NKTR.

This podcast is powered by Pinecast.